{"id":979,"date":"2022-07-20T11:49:14","date_gmt":"2022-07-20T09:49:14","guid":{"rendered":"https:\/\/www.yokogawa.com\/eu\/blog-staging\/life-innovation\/2022\/07\/20\/car-t-cells\/"},"modified":"2022-07-22T09:49:35","modified_gmt":"2022-07-22T07:49:35","slug":"car-t-cells","status":"publish","type":"post","link":"https:\/\/www.yokogawa.com\/eu\/blog\/life-innovation\/car-t-cells\/","title":{"rendered":"CAR T-cells: A New Era in Cancer Therapy?"},"content":{"rendered":"\n

What are T-cells?<\/strong><\/h2>\n\n\n\n

T-cells are white blood cells, called lymphocytes, that are part of the immune system and help to fight against infection but also cancer cells. The defective cells are recognized by T-cells and are removed by the immune system afterward. But unfortunately, cancer cells gain the ability to escape from the recognition by T-cells and therefore can expand in the body.<\/p>\n\n\n\n

CAR T-cells<\/strong><\/p>\n\n\n\n

Finding new ways to get T-cells to recognize cancer cells is a solution for treating cancer patients and one possible way to do this might be CAR T-cell therapy.<\/p>\n\n\n\n

In the first step, T-cells are collected from the patient. Then the T-cells are genetically engineered into CAR T-cells. CAR stands for chimeric antigen receptor that is able to recognize specific proteins (antigens) on the cell surface of the cancer cell. The CAR T-cells then are given back to the patient by intravenous infusion.<\/p>\n\n\n\n

CAR T-cell therapy has shown impressive results in leukemia but for solid tumors, new preclinical models are needed. Henner Farin et al. (published in EMBO, 2019) could prove a new 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. The researchers developed a platform to study CAR cell cytotoxicity against 3-dimensional (3D) patient-derived colon organoids.<\/p>\n\n\n\n

\n